Glecaprevir/pibrentasvir for PTSD

Based on the public registry summary, this study is trying to understand: A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic. The study team can confirm the exact objective and what it means for you.

This appears to be a behavioral / psychological / psychosocial study involving Glecaprevir/pibrentasvir, Placebo. The listed phase is PHASE2. Ask the study team what that means in practice for safety, monitoring, and criteria.

This study may concern people with ptsd; age range: From 19 Years to 70 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

You may take part in sessions or exercises related to habits, thoughts, emotions, or behaviors. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Behavioral studies can involve habits, emotions, motivation, stress, sleep, or ways of thinking. Ask whether the intervention could affect your mood or stress, and who to contact if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by White River Junction Veterans Affairs Medical Center, which appears to be a hospital or academic medical center. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps. The registry lists an estimated enrollment of 92 participants.